Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 4 · below the Ichimoku cloud · RSI 31 · MACD below its signal
None of the 29 investors followed here reported a position in AARD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AARD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Sun Nelson B.Chief Operating Officer | Sale at price 5.00 - 5.18 per share. | 76.8K | $394.96K |
| Dec 10, 2025 | Lee Tien-LiChief Executive Officer | Purchase at price 14.48 per share. | 7K | $101.39K |
| Dec 10, 2025 | Sun Nelson B.Chief Financial Officer | Purchase at price 14.40 per share. | 3K | $43.20K |
| Oct 14, 2025 | Lee Tien-LiChief Executive Officer | Conversion of Exercise of derivative security at price 4.24 per share. | 1.2K | $5.21K |
| Oct 14, 2025 | Jones BryanChief Operating Officer | Conversion of Exercise of derivative security at price 4.24 per share. | 1.3K | $5.30K |
| Sep 14, 2025 | Lee Tien-LiChief Executive Officer | Purchase at price 9.51 - 9.94 per share. | 10K | $96.62K |
| Sep 11, 2025 | Lee Tien-LiChief Executive Officer | Purchase at price 7.82 - 8.50 per share. | 20K | $160.65K |
| Sep 8, 2025 | Sun Nelson B.Chief Financial Officer | Purchase at price 8.07 per share. | 6K | $48.44K |
| Aug 27, 2025 | Lee Tien-LiChief Executive Officer | Conversion of Exercise of derivative security at price 4.24 per share. | 17.2K | $72.97K |
| Feb 13, 2025 | Cormorant Asset Management ,L.PUnknown | — | 800.2K | — |
| Feb 13, 2025 | Vickers Venture Fund Vi Pte, Ltd.Beneficial Owner of more than 10% of a Class of Security | — | 2.05M | — |
| Feb 13, 2025 | Decheng Capital Global Life Sciences Fund Iv, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 2.67M | — |
| Feb 13, 2025 | Lee Tien-LiChief Executive Officer | — | 41.3K | — |
| Feb 13, 2025 | Chi Jeffrey Chien Chuen Ph.D.Director | — | 133.4K | — |
| Feb 13, 2025 | Sun Nelson B.Chief Financial Officer | — | 7K | — |
| Feb 13, 2025 | Cormorant Asset Management ,L.PUnknown | Purchase at price 13.30 per share. | 187.5K | $2.49M |
| Feb 13, 2025 | Decheng Capital Global Life Sciences Fund Iv, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 13.30 per share. | 1.25M | $16.63M |
| Feb 13, 2025 | Lee Tien-LiChief Executive Officer | Purchase at price 13.30 per share. | 16.5K | $220.01K |
| Feb 13, 2025 | Sun Nelson B.Chief Financial Officer | Purchase at price 13.30 per share. | 10K | $133.00K |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Buy / hold / sell counts